Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456248 · ClinicalTrials.gov registry record · Phase 4
Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin
A Phase 4 study, sponsored by Kadmon Corporation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT00456248 is a Phase 4 study that was terminated before completion, run by Kadmon Corporation. The registered enrollment target is 5 participants.
The verdict
NCT00456248, a Phase 4 study, was terminated before completion, sponsored by Kadmon Corporation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a 60-to-72 week multicenter study to evaluate Infergen and Ribavirin in patients with Chronic Hepatitis C Virus after partial response to treatment using peginterferon-alfa and Ribavirin therapy. The study will be conducted at approximately 50 sites across the United States.
Interventions
- DRUG Infergen and ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456248
The ClinicalTrials.gov registry entry for NCT00456248 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infergen and ribavirin is the first listed.
NCT00456248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00456248 about?
NCT00456248 is a clinical study titled "Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin". This is a 60-to-72 week multicenter study to evaluate Infergen and Ribavirin in patients with Chronic Hepatitis C Virus after partial response to treatment using peginterferon-alfa and Ribavirin therapy. The study will be conducted at approximately 50 sites across the United States.
What is the current status of trial NCT00456248?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2007-02. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00456248?
The interventions under investigation include: Infergen and ribavirin (DRUG).
Who is sponsoring clinical trial NCT00456248?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.